RxDoctor Payments Data

Lupe Yepez-Michel, NP

Nurse Practitioner · Ventura, CANPI 1952481053

Payments from drug & device makers

$8,853in general payments, 2019–2025

Across 105 payments — averaging $84.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$888
  • AstraZeneca$859
  • AbbVie$645
  • Lilly USA, LLC$540
  • GSK$474
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$8,851100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,853 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$26,137
Medicare patients
169
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$13,832
Quetiapine Fumarate146$2,499
Gabapentin133$2,077
Hydroxyzine Hcl96$1,992
Aripiprazole39$1,302
Bupropion XlBupropion Hcl82$1,147
Duloxetine Hcl57$1,053
Trazodone Hcl143$1,006
Buspirone Hcl95$723
Atorvastatin Calcium91$697
Lurasidone Hcl16$639
Amitriptyline Hcl14$638
Lamotrigine75$638
Escitalopram Oxalate87$610
Fluoxetine Hcl96$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$174$13,83226 claims
Almatica Pharma LLCSertraline Hcl$22$46569 claims
Lilly USA, LLCOlanzapine$540$44517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →